Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2017 Dec 7

PMID 29209921

Citations 6

Authors

Aisaku Osamura

Yasuo Suzuki

Affiliations

Soon will be listed here.

Abstract

Background: Crohn's disease (CD) is an intractable disease that requires long-term treatment. Tumor necrosis factor (TNF) inhibitors have strong efficacy and are widely used for CD treatment. However, a loss of response is one of the issues in long-term TNF therapy. To identify the factors affecting the efficacy of long-term CD treatment with TNF inhibitors, we conducted a retrospective study of treatment outcomes and clinical factors using clinical data over a 14-year period.

Methods: Clinical characteristics and factors for surgery, hospitalization, and TNF inhibitor treatment discontinuation were examined in 219 biologic-naïve patients who were treated with TNF inhibitors at our hospital before October 2014.

Results: Treatment persistence rates with no hospitalization, surgery, or dose escalation were 60.7, 25.9, and 17.3% for 1, 5, and 10 years, respectively; these rates did not differ between infliximab (IFX) and adalimumab. In patients receiving IFX dose escalation, 1- and 5-year persistence rates were approximately 90.4 and 65.1%, respectively. Previous surgery (OR = 1.45, P = 0.043) was identified as a risk factor for surgery, male sex (OR = 0.70, P = 0.044) and previous surgery (OR = 1.51, P = 0.03) were risk factors for hospitalization, and perianal fistula (OR = 1.39, P = 0.049) was the risk factor for TNF inhibitor treatment discontinuation.

Conclusions: The durability of anti-TNF therapy in CD patients remains a problem, and treatment optimization that includes dose escalation should be carefully examined depending on patient characteristics and the timing of optimization.

Citing Articles

Salem D, El-Ijla R, AbuMusameh R, Zakout K, Abu Halima A, Abudiab M BMC Gastroenterol. 2024; 24(1):425.

PMID: 39580396 PMC: 11585250. DOI: 10.1186/s12876-024-03514-2.

Impact of sex and socioeconomic status on the likelihood of surgery, hospitalization, and use of medications in inflammatory bowel disease: a systematic review and meta-analysis.

Rasmussen N, Moos C, Gregersen L, Hikmat Z, Andersen V, Green A Syst Rev. 2024; 13(1):164.

PMID: 38915086 PMC: 11194997. DOI: 10.1186/s13643-024-02584-3.

Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.

Panaccione R, Lee W, Clark R, Kligys K, Campden R, Grieve S Adv Ther. 2023; 40(5):2051-2081.

PMID: 36930430 PMC: 10129944. DOI: 10.1007/s12325-023-02457-6.

Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.

Nakase H, Esaki M, Hirai F, Kobayashi T, Matsuoka K, Matsuura M J Gastroenterol. 2023; 58(4):313-345.

PMID: 36773075 PMC: 10050046. DOI: 10.1007/s00535-023-01958-z.

Long-term clinical and real-world experience with Crohn's disease treated with anti-tumor necrosis factor-α antibodies.

Otake H, Matsumoto S, Mashima H Intest Res. 2022; 20(4):464-474.

PMID: 35350094 PMC: 9650333. DOI: 10.5217/ir.2021.00139.

References

Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N . Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. J Crohns Colitis. 2016; 10(11):1259-1266. DOI: 10.1093/ecco-jcc/jjw152. View

Greenstein A, Lachman P, Sachar D, Springhorn J, Heimann T, Janowitz H . Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut. 1988; 29(5):588-92. PMC: 1433651. DOI: 10.1136/gut.29.5.588. View

Veloso F, Ferreira J, Barros L, Almeida S . Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis. 2001; 7(4):306-13. DOI: 10.1097/00054725-200111000-00005. View

Peyrin-Biroulet L, Cieza A, Sandborn W, Coenen M, Chowers Y, Hibi T . Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2011; 61(2):241-7. PMC: 3245899. DOI: 10.1136/gutjnl-2011-300049. View

Solberg I, Vatn M, Hoie O, Stray N, Sauar J, Jahnsen J . Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5(12):1430-8. DOI: 10.1016/j.cgh.2007.09.002. View

Ben-Horin S, Chowers Y . Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33(9):987-95. DOI: 10.1111/j.1365-2036.2011.04612.x. View

Dulai P, Siegel C, Peyrin-Biroulet L . Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am. 2014; 43(3):441-56. DOI: 10.1016/j.gtc.2014.05.009. View

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S . Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial. Inflamm Bowel Dis. 2015; 21(9):2114-22. DOI: 10.1097/MIB.0000000000000475. View

10.

Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J, Cosnes J . Predictors of Crohn's disease. Gastroenterology. 2006; 130(3):650-6. DOI: 10.1053/j.gastro.2005.12.019. View

11.

Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip J, Peyrin-Biroulet L . Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015; 9(7):525-31. DOI: 10.1093/ecco-jcc/jjv061. View

12.

Louis E, Michel V, Hugot J, Reenaers C, Fontaine F, Delforge M . Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003; 52(4):552-7. PMC: 1773596. DOI: 10.1136/gut.52.4.552. View

13.

Chow D, Sung J, Wu J, Tsoi K, Leong R, Chan F . Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis. 2008; 15(4):551-7. DOI: 10.1002/ibd.20804. View

14.

Romberg-Camps M, Dagnelie P, Kester A, Hesselink-van de Kruijs M, Cilissen M, Engels L . Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009; 104(2):371-83. DOI: 10.1038/ajg.2008.38. View

15.

Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N . C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol. 2013; 49(2):254-62. DOI: 10.1007/s00535-013-0807-0. View

16.

Hazlewood G, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow C . Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology. 2014; 148(2):344-54.e5. DOI: 10.1053/j.gastro.2014.10.011. View

17.

Dulai P, Siegel C, Colombel J, Sandborn W, Peyrin-Biroulet L . Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014; 63(12):1843-53. DOI: 10.1136/gutjnl-2014-307126. View